Vnitřní lékařství 1/2020

HLAVNÍ TÉMA Diabetes mellitus 2. typu v praxi – balancovánímezi rezistencí a sekrecí | 27  / Vnitř Lék 2020; 66(1): 21–27 /  VNITŘNÍ LÉKAŘS TVÍ www.casopisvnitrnilekarstvi.cz Noninsulin‑Dependent Diabetes Mellitus 1. The Journal of Clinical Endocrinology & Me‑ tabolism 1998; 83: 744–750. 16. Ahren B, Pratley R, Soubt M et al. Clinical Measures of Islet Function: Usefulness to Cha‑ racterize Defects in Diabetes. Current Diabetes Reviews 2008; 4: 129–145. 17. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: inzulin re‑ sistance and beta‑cell function from fasting plasma glucose and inzulin concentrations in man. Diabetologia 1985; 28: 412–419. 18. Wallace TM, Levy JC, Matthews DR. Use and Abuse of HOMA Modeling. Diabetes Care 2004; 27: 1487–1495. 19. Levy JC, Matthews DR, Hermans MP. Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program. Diabetes Care 1998; 21: 2191–2192. 20. Katz A, Nambi SS, Mather K, et al. Quantitative Insulin Sensitivity Check Index: A Sim‑ ple, Accurate Method for Assessing Insulin Sensitivity In Humans. The Journal of Clinical Endocrinology & Metabolism 2000; 85: 2402–2410. 21. Chen H, Sullivan G, Quon MJ. Assessing the Predictive Accuracy of QUICKI as a Surro‑ gate Index for Insulin Sensitivity Using a Calibration Model. Diabetes 2005; 54: 1914–1925. 22. Matsuda M, Defronzo RA. Insulin sensitivity indices obtained from oral gluco‑ se tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462–1470. 23. Lorenzo C, Haffner SM, Stančáková A et al. Fasting and OGTT‑derived Measures of In‑ sulin Resistance as Compared With the Euglycemic‑Hyperinsulinemic Clamp in Nondia‑ betic Finnish Offspring of Type 2 Diabetic Individuals. The Journal of Clinical Endocrino‑ logy & Metabolism 2015; 100: 544–550. 24. Xiang AH, Watanabe RM, Buchanan TA. HOMA and Matsuda indices of insulin sensiti‑ vity: poor correlation with minimal model‑based estimates of insulin sensitivity in longi‑ tudinal settings. Diabetologia 2014; 57: 334–338. 25. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and β‑cell fun‑ ction. Best Practice & Research Clinical Endocrinology & Metabolism 2003; 17: 305–322. 26. Bruinstroop E, Meyer L, Brouwer CB et al. Retrospective Analysis of an Insulin‑to‑Liraglutide Switch in Patients with Type 2 Diabetes Mellitus. Diabetes Therapy 2018; 9: 1369–1375. 27. Kawata T, Kanamori A, Kubota A et al. Is a Switch From Insulin Therapy to Liraglutide Possible in Japanese Type 2 Diabetes Mellitus Patients? Journal of Clinical Medicine Re‑ search 2014; E744. 28. Iwao T, Sakai K, Sata M. Postprandial serum C‑peptide is a useful parameter in the pre‑ diction of successful switching to liraglutide monotherapy from complex insulin thera‑ py in Japanese patients with type 2 diabetes. Journal of Diabetes and its Complications 2013; 27: 87–91. 29. Davis SN, Johns D, Maggs D et al. Exploring the Substitution of Exenatide for Insulin in Patients With Type 2 Diabetes Treated With Insulin in Combination With Oral Antidiabe‑ tes Agents. Diabetes Care 2007; 30: 2767–2772. 30. Araki H, Tanaka Y, Yoshida S et al. Oral glucose‑stimulated serum C‑peptide predicts suc‑ cessful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment. Journal of Diabetes Investigation 2014; 5: 435–441. 31. Aron‑Wisnewsky J, Sokolovska N, Liu Y et al. The advanced‑DiaRem score impro‑ ves prediction of diabetes remission 1 year post‑Roux‑en‑Y gastric bypass. Diabetolo‑ gia 2017; 60: 1892–1902. 32. Dicker D, Golan R, Aron‑Wisnewsky J et al. Prediction of Long‑Term Diabetes Remissi‑ on After RYGB, Sleeve Gastrectomy, and Adjustable Gastric Banding Using DiaRem and Advanced‑DiaRem Scores. Obesity Surgery 2019; 29: 796–804. 33. Steven S, Hollingsworth Kg, Al‑Mrabeh A et al. Very Low‑Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. Diabetes Care 2016; 39: 808–815. 20. - 21. 3. 2020 hotel Holiday Inn Brno DI BETES nář Brno 2020 X mu kontinuálního ní účasti na tomto vzdělávání lékařů. Věříme, že přijmete naše pozvání k aktiv čenského hlediska. semináři, který pro Vás bude přínosem z odborného i spole Těšíme se na setkání s Vámi. Přihlášky a informace na brno.cz www.dia www.diabrno.cz | e-mail: info@diabrno.cz | tel.: 775 553 61 Seminář organizuje: Lion Media, s.r.o. | www.lionmedia.cz